Research Outputs (100)

Sort by: Date | Title

10 | 25 | 50 | 100

1/10

A B C D E G H I J K L M N O P R S T U V W All

ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN LUX-LUNG 3, A PHASE III TRIAL OF AFATINIB OR CISPLATIN/PEMETREXED IN EGFR MUTATION-POSITIVE LUNG CANCER
Yang JC, Schuler M, Yamamoto N, O'Byrne KJ, Hirsh V, Mok TSK, Massey D, Zazulina V, Shahidi M, Sequist LV ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
A disintegrin-like and metalloprotease with thrombospondin type 1 motif 9 is a functional tumor suppressor in gastric cancer through inhibiting AKT/mTOR pathway
DU Wan, WANG, Shiyan, LI Xiaoxing, TAO Qian, FANG Jing-yuan Fang, SUNG Joseph Jao-yiu, YU Jun ( 2012 )
The Digestive Disease Week
Other conference paper
A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT)
Chan A.T.C., Ngan R. K. C., Hui E. P., Leung S. F., Poon P., Sin V. C., Tung S. Y., Cheng A. C. K., Yau T. K., Lee V., Ma B., Cheng H. C., Yuen K. K., Lee C., Kam M. K., Yau S., Ng A. W. Y., Mo F., Zee B. C. Y., Lo D. Y. M. ( 2012 )
Annual Meeting of American Society of Clinical Oncology
Invited conference paper presented and published in conference proceedings
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
KIM P George, MAHONEY R Michelle, SZYDLO Daniel, MOK Shu Kam Tony, MARSHKE Robert, HOLEN Kyle, PICUS Joel, BOYER Michael, PITOT C Henry, RUBIN Joseph, PHILIP A Philip, NOWAK Anna, WRIGHT J John, ERLICHMAN Charles ( 2012 )
invest new drugs
Publication in refereed journal
A Novel 19q13 Nucleolar Zinc Finger Protein Suppresses Tumor Cell Growth through Inhibiting Ribosome Biogenesis and Inducing Apoptosis but Is Frequently Silenced in Multiple Carcinomas
Cheng YD, Liang P, Geng H, Wang ZH, Li LL, Cheng SH, Ying JM, Su XW, Ng KM, Ng MHL, Mok TSK, Chan ATC, Tao Q ( 2012 )
MOLECULAR CANCER RESEARCH
Publication in refereed journal
Digital Object Identifier (DOI): http://dx.doi.org/10.1158/1541-7786.MCR-11-0594
Anti-HER2: Agents in the Horizon
YEO Winnie ( 2012 )
3rd Oncology Forum of Hong Kong
Invited conference paper presented and published in conference proceedings
A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma
Ma BBY, Kam MKM, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BKH, Ahuja A, Chan ATC ( 2012 )
ANNALS OF ONCOLOGY
Publication in refereed journal
Digital Object Identifier (DOI): http://dx.doi.org/10.1093/annonc/mdr401
A phase II study of transarterial chemoembolization and axitinib for the treatment of unresectable hepatocellular carcinoma
CHAN Lam Stephen, YEO Winnie, HUI Joyce, LI Leung, LOONG Herbert, HUI Pun Edwin, CHAN Anthony Tak Cheung, MOK Shu Kam Tony, YU Simon ( 2012 )
Annual Meeting of the American Society of Clinical Oncology
Refereed conference paper presented and published in conference proceedings
A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma
LIM Ho Yeong, YEN Chia Jui, TAK Won Young, HEO Jeong, CHOI Hye Jin, LIN Cheng Yao, YOON Jung Hwan, HSU Chiun, RAU Kun Ming, POON Ronnie, YEO Winnie, PARK Joong Won, TAY Miah Hiang, HSIEH Wen Son, KAPPELER Christian, RAJAGOPALAN Prabhu, KRISSEL Heiko ( 2012 )
Annual Meeting of the American Society of Clinical Oncology
Refereed conference paper presented and published in conference proceedings
A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma
LIM H Y, YEN C J, TAK W Y, HEO J, CHOI H J, LIN C Y, YOON J H, HSU C, RAU K M, POON R, YEO Winnie, PARK J W, TAY M H, HSIEH W S, KAPPELER C, RAJAGOPALAN P, KRISSEL H ( 2012 )
Annual Meeting of the American Society of Clinical Oncology
Refereed conference paper presented and published in conference proceedings

10 | 25 | 50 | 100

1/10

Research Outputs (100)

Share Link

Our policy towards the use of cookies